Aclarion Raises $10.4M, Extends Cash Runway Into 2028

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structure.

The transaction materially strengthens Aclarion's balance sheet, preserves capital structure integrity, and significantly extends the Company's operating runway well past targeted near and medium-term catalysts while enhancing strategic flexibility as Nociscan continues to gain clinical and commercial traction. The Company believes its strengthened capital position fully supports continued execution across commercialization, evidence generation, and strategic partnerships in the lead up toward additional payor coverage.

Financial Highlights

• $21.6 million in cash as of January 12, 2026
• Zero debt
• Cash runway extended into 2028 based on current operating plans
  
  
  
   

"We have transformed Aclarion's balance sheet over the past year and positioned the Company for long-term value creation with a pristine capital structure," said Brent Ness, Chief Executive Officer of Aclarion.



"This financing clearly de-risks our ability to reach significant milestones within the timeline of our cash runway. With a debt-free balance sheet, strong cash reserves, and extended cash runway into 2028, we are focused squarely on execution, expanding adoption of Nociscan, deepening clinical evidence, and building strategic relationships that drive durable growth for patients, providers, payers, and shareholders."

Upcoming Milestones and Key Value-Creation Objectives

• Advance clinical validation efforts:
  • Accelerate enrollment in the CLARITY trial with goal of enrolling approximately 25% of patients by the end of Q2 2026. An initial readout will be internally available after the initial cohort of patients complete their 3-month follow up visit.
  • Complete and publish multiple investigator-initiated real world evidence trials.
  • Expand major MRI manufacturer access, growing the available global market size by greater than 30%.
• Support broader clinician education and awareness initiatives through accelerated participation at societal-sponsored CME events.
• Continue refining workflow integration to support scalability in clinical practice by launching version 2.8 of our Nociscan software in Q1.
• Actively collaborate with multiple commercial payers in the US market to evaluate broad reimbursement coverage of Nociscan.
  
  
  
   

Dawson James Securities, Inc. acted as the exclusive placement agent for the offering.